MORRISVILLE -
Conducted annually, the Survey provides a review of biopharmaceutical dealmakers' expectations for deal activity in the year ahead.
The 2024 Survey indicates cautious optimism for biopharmaceutical dealmaking, driven by forward-looking
'Our research shows an increasing likelihood for biopharmaceutical companies to explore strategic, non-dilutive transactions to further advance their assets,' said
Demand for endocrine/metabolic assets, particularly diabetes drugs repositioned as weight-loss and cardiovascular disease solutions, will remain high.
Antibody-drug conjugates, and machine-learning enabled products - including GenAI and microbiome-related technologies - will be prime acquisition targets.
Interest in Cell & Gene therapy technologies will remain strong.
About
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients.
Contact:
Tel: +1 908 763 3428
Email: gary.gatyas@syneoshealth.com
(C) 2024 Electronic News Publishing, source